Management Quality -- 8/10
CEO Robert Fauber has led Moody's since January 2021, navigating the severe 2022 issuance
downturn (MIS revenue -28%) and delivering a powerful recovery with MIS revenue surpassing
its FY2021 peak. Consolidated adjusted margins expanded 850bps from the FY2022 trough to
51.1% in FY2025, while MA was transformed into a 97% recurring-revenue platform through
organic investment and disciplined portfolio pruning. Capital allocation is shareholder-aligned
with ~$2B in FY2026 buybacks and a 10% dividend increase.
Weight: 20%
CEO Tenure
~5 Years
Robert Fauber, CEO since Jan 2021
Margin Expansion
+850bps
42.6% (FY2022) to 51.1% (FY2025)
MA Margin Trajectory
29.7% to 35.7%
8-quarter expansion, Q1 2024 to Q4 2025
FY2026 Buyback
~$2B
90%+ FCF returned to shareholders
Fauber Track Record
| Initiative | Result | Status |
|---|---|---|
| 2022 Downturn Navigation | MIS revenue fell from $3.98B to $2.87B (-28%). Preserved franchise, continued technology investment, maintained cost discipline through the trough. | DELIVERED |
| MIS Recovery Above Peak | MIS revenue reached $4.32B in FY2025, surpassing the FY2021 peak of $3.98B (+8%). MIS adjusted margins hit 63.6% in FY2025, above the medium-term target of low-60s. | DELIVERED |
| MA Recurring Revenue Transformation | MA recurring revenue now 97% of total (up from ~90% pre-Fauber). Decision Solutions ARR grew from ~$1.1B to $1,579M. Launched Maxsight corporate platform. | DELIVERED |
| Portfolio Pruning | Divested Learning Solutions (non-core transactional) and Regulatory Reporting (limited cross-sell). Concentrated portfolio on higher-growth, higher-margin businesses. | DELIVERED |
| MA Margin Expansion | MA margins expanded from ~28% to ~36% over 8 quarters while investing in GenAI, new products, and international expansion. FY2026 guide: 34-35%. | ON TRACK |
From Q1 2025 transcript (Fauber on tariff uncertainty): "We have managed through all these
air pockets over the years... we have more ability now to preserve operating leverage within
a band." Guided MIS margins to 61-62% even in a softer issuance scenario.
Source: Daloopa, earnings call transcripts FY2022-FY2026.
Capital Allocation
Moody's returns capital aggressively, guiding ~$2B in FY2026 share repurchases alongside a
10% dividend increase. Management is returning 90%+ of free cash flow to shareholders. From
Q4 2025 transcript (Fauber): "Given the recent market activity, our strong fundamentals and
durable growth outlook, you can expect us to be aggressively buying back shares at these
levels."
| Metric | Value | Detail |
|---|---|---|
| FY2026 Share Repurchases | ~$2B | Guided, aggressive at current prices |
| FY2026 Dividend Increase | 10% | Consistent annual increases |
| FCF Return to Shareholders | 90%+ | Buybacks + dividends as pct of FCF |
| FY2025 FCF | $2,575M | 33% FCF margin; FY2026 guide $2.8-3.0B |
Source: Daloopa, Q4 2025 earnings call transcript.
Minor Concern
MA ARR growth deceleration. Total MA ARR growth has moderated from
mid-teens to 7% YoY ($3,498M in Q4 2025 vs $3,278M in Q4 2024). Some investor frustration
that GenAI has not yet translated into visible ARR acceleration. In Q4 2025 Q&A, Fauber
pointed to leading indicators -- largest strategic customers contributing 30%+ of MA net
growth and growing at 2x the rate of the rest, and AI-solution cohort growing at 2x --
rather than hard revenue numbers. Decision Solutions ARR growth has also slowed from
double-digits to 9%. This bears monitoring but does not undermine the broader execution
story.
Score Rationale
8/10. Robert Fauber (CEO since Jan 2021) has delivered an impressive
turnaround from the 2022 issuance downturn: MIS revenue recovered above its FY2021 peak,
consolidated margins expanded 850bps in three years, and MA was transformed into a 97%
recurring-revenue platform. Portfolio pruning (Learning Solutions, Regulatory Reporting
divestitures) demonstrates capital discipline. Capital allocation is shareholder-aligned
with ~$2B annual buybacks, a 10% dividend increase, and 90%+ FCF return. CFO Noemie
Heuland provides strong operational transparency and granular guidance cadence. The score
is held at 8 (not higher) because MA ARR growth has decelerated from mid-teens to
high-single-digits, and GenAI monetization has not yet visibly inflected the top line
despite encouraging leading indicators. Issuance cycle management is a proven strength,
but the inherent cyclicality of MIS limits the ceiling for management scoring.
Data sourced from Daloopa, earnings call transcripts, and company disclosures.